MX2023010535A - Antisense oligonucleotides for inhibiting alpha-synuclein expression. - Google Patents
Antisense oligonucleotides for inhibiting alpha-synuclein expression.Info
- Publication number
- MX2023010535A MX2023010535A MX2023010535A MX2023010535A MX2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A MX 2023010535 A MX2023010535 A MX 2023010535A
- Authority
- MX
- Mexico
- Prior art keywords
- antisense oligonucleotides
- synuclein expression
- inhibiting alpha
- synuclein
- alpha
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 title abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 title abstract 2
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 2
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present disclosure provides antisense oligonucleotides for regulating expression of alpha-synuclein and use thereof to treat synucleinopathies.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21315033 | 2021-03-08 | ||
EP21306123 | 2021-08-17 | ||
PCT/EP2022/055770 WO2022189363A1 (en) | 2021-03-08 | 2022-03-07 | Antisense oligonucleotides for inhibiting alpha-synuclein expression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010535A true MX2023010535A (en) | 2023-09-19 |
Family
ID=80738805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023010535A MX2023010535A (en) | 2021-03-08 | 2022-03-07 | Antisense oligonucleotides for inhibiting alpha-synuclein expression. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4305168A1 (en) |
JP (1) | JP2024508956A (en) |
AU (1) | AU2022234522A1 (en) |
CA (1) | CA3212650A1 (en) |
CL (1) | CL2023002644A1 (en) |
IL (1) | IL305668A (en) |
MX (1) | MX2023010535A (en) |
PE (1) | PE20240696A1 (en) |
TW (1) | TW202305132A (en) |
WO (1) | WO2022189363A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE239484T1 (en) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | DERIVATIZED OLIGONUCLEOTIDES WITH IMPROVED ABSORPTION CAPACITY |
EP3561060A1 (en) * | 2010-02-08 | 2019-10-30 | Ionis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
EP2673361B1 (en) * | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
EP3336189A1 (en) * | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
CN104884618A (en) | 2012-11-15 | 2015-09-02 | 罗氏创新中心哥本哈根有限公司 | Oligonucleotide conjugates |
RU2650510C2 (en) | 2013-05-01 | 2018-04-16 | Ионис Фармасьютикалз, Инк. | Compositions and methods of modulating apolipoprotein c-iii expression |
EP3591054A1 (en) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Antisense oligomers and conjugates targeting pcsk9 |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
US20200040061A1 (en) * | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
TWI809004B (en) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
SG11202006142PA (en) * | 2018-01-12 | 2020-07-29 | Roche Innovation Ct Copenhagen As | Alpha-synuclein antisense oligonucleotides and uses thereof |
WO2020227395A2 (en) | 2019-05-06 | 2020-11-12 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
-
2022
- 2022-03-07 CA CA3212650A patent/CA3212650A1/en active Pending
- 2022-03-07 JP JP2023554365A patent/JP2024508956A/en active Pending
- 2022-03-07 MX MX2023010535A patent/MX2023010535A/en unknown
- 2022-03-07 EP EP22710115.1A patent/EP4305168A1/en active Pending
- 2022-03-07 TW TW111108274A patent/TW202305132A/en unknown
- 2022-03-07 IL IL305668A patent/IL305668A/en unknown
- 2022-03-07 PE PE2023002509A patent/PE20240696A1/en unknown
- 2022-03-07 AU AU2022234522A patent/AU2022234522A1/en active Pending
- 2022-03-07 WO PCT/EP2022/055770 patent/WO2022189363A1/en active Application Filing
-
2023
- 2023-09-05 CL CL2023002644A patent/CL2023002644A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4305168A1 (en) | 2024-01-17 |
IL305668A (en) | 2023-11-01 |
CA3212650A1 (en) | 2022-09-15 |
PE20240696A1 (en) | 2024-04-10 |
WO2022189363A1 (en) | 2022-09-15 |
TW202305132A (en) | 2023-02-01 |
JP2024508956A (en) | 2024-02-28 |
CL2023002644A1 (en) | 2024-04-01 |
AU2022234522A1 (en) | 2023-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022004101A (en) | Oligonucleotide compositions and methods of use thereof. | |
MX2023001917A (en) | Shp2 phosphatase inhibitors and methods of use thereof. | |
PH12020500570A1 (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
MX2016017288A (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents. | |
EP2633052A4 (en) | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 | |
MX358603B (en) | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene. | |
MX2011009751A (en) | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. | |
MX2023005636A (en) | Benzimidazolone derived inhibitors of bcl6. | |
GEP20186864B (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
MX2011009752A (en) | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1. | |
PT1297851E (en) | INHIBITION OF HISTONE-DESACETILASE AS TREATMENT FOR CARDIAC HYPERTROPHY | |
GEP20237541B (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
MX2022001004A (en) | Enzyme inhibitors. | |
PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
WO2012047956A3 (en) | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 | |
MX2021016049A (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer. | |
SG11201906787UA (en) | Injectable composition for preventing hair loss or stimulating hair growth | |
MX2020008991A (en) | Methods for altering body composition. | |
MX2021013901A (en) | Compositions and methods for treating cancer. | |
MX2020007439A (en) | Antisense oligonucleotides targeting alpha-synuclein and uses thereof. | |
MX2013010524A (en) | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer. | |
SA520412423B1 (en) | Antisense oligonucleotides targeting alpha-synuclein and uses thereof | |
BR112022009607A2 (en) | AKT INHIBITORS TO IMPROVE CHIMERIC T-CELL PERSISTENCE | |
MX2022005450A (en) | Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders. | |
MX2022002069A (en) | Enzyme inhibitors. |